AlphAIAlphAI — Financial news for AI agents
stocktitan.netAUG 211 min read$TK

Teekay (NYSE: TK) director plans sale of 2,581 NYSE shares

Teekay (NYSE: TK) director Heidi Locke Simon plans to sell 2,581 shares, acquired as Restricted Units on 06/17/2025, through Morgan Stanley Wealth Management Canada Inc. The sale is expected to occur on 08/21/2026, with an approximate market value of $34,043.39.

Original reporting
stocktitan.net
Published Aug 21, 2026, 12:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 2:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TK
Neutral
high confidence
Mentioned
$TK
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TKNeutralLow
01

Why it matters

A small insider sale typically has limited market impact but may signal future supply.

02

Market read

Routine insider sale with modest size; low trading relevance.

03

What to watch

Potential lock‑up expiration of other insiders or upcoming corporate actions could amplify impact.

Relevance 4/10Novelty 3/10Timing: sale planned for 08/21/2026

Background

Form 144 disclosures signal when restricted insider shares may enter the market.

Company-level read

Ticker impact

$TKNeutralHigh confidence
Context

Director Heidi Locke Simon filed a Form 144 to sell 2,581 TK shares (~$34k) on 08/21/2026.

Expected impact

minimal downward pressure

Evidence & confidence

The sale size is small relative to float and market cap, so price effect is expected to be limited.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be interpreted as insider confidence if the director expects price appreciation before the sale.

Key entities

  • Director
    Heidi Locke Simon

    Teekay director filing a Rule 144 sale.

  • Company
    Teekay Corp Ltd

    Issuer of the shares being sold.

Read at source← All news

Related articles

AUG 8
$TKMedAI 8/10

Teekay (TK) Q2 2026 Earnings Call Transcript

Teekay Corporation (TK) reported Q2 2026 GAAP net income of $226 million ($6.49/share) including a $32.3 million gain from selling a Suezmax vessel. Adjusted net income was $194 million ($5.56/share), up 50% vs. the prior quarter. The company generated $200 million in free cash flow, ended with $1.2 billion cash and zero debt, and committed $190 million for two Suezmax newbuildings.

fool.com9 min
JUL 30
$TKMed

War-driven spike in tanker rates drives Teekay’s soaring profits

Teekay Corporation reported Q2 net income attributable to shareholders of $69.5M, or 79 cents/share, vs $18.7M, or 22 cents/share, a year earlier. Revenue rose to $379.1M from $232.2M and operating income to $220.8M from $52.7M, driven by Teekay Tankers’ record spot tanker rates amid Middle East disruptions. Suezmax averaged $109,200/day and Aframax/LR2 $74,100/day. Teekay Tankers booked newbuilds for $190M and sold vessels, adding gains.

royalgazette.com4 min
JUL 29
$TKHigh

TEEKAY CORP LTD (TK): Financial results for Q2 2026

TEEKAY CORP LTD (TK) furnished an SEC Form 6-K — earnings release. Item 1 — Information Contained in this Form 6-K Report Attached as Exhibit 1 is a copy of an announcement of Teekay Corporation Ltd. dated July 29, 2026. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to b

SEC EDGAR 6-K2 min
MAY 28
$TKMedAI 8/10

Teekay (NYSE:TK) Shares Gap Down – Here’s Why

Teekay Corp.’s (NYSE:TK) shares opened lower Tuesday after closing at $13.34 and gapping down to $12.38; the stock last traded at $12.50. Wall Street Zen downgraded TK from buy to hold, according to MarketBeat. Teekay reported $0.55 EPS on May 13 and announced a $1.00 special dividend payable June 2.

dailypolitical.com4 min
OCT 3
$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

investing.com2 min